Crossject
Dijon, FranceFounded 2001Industry
Crossject is a French maker of needle-free auto-injectors. Under a BARDA Project BioShield partnership it is developing ZENEO midazolam autoinjectors for emergency use, such as nerve-agent seizures.
What it does
Threats covered
Categories
Profile
Crossject is a Dijon-based specialty pharmaceutical company founded in 2001 and listed on Euronext Growth Paris under ALCJ. It develops ZENEO, a needle-free auto-injector for emergency medicines.
More profile
Its lead product, ZEPIZURE (midazolam), is in advanced regulatory development with BARDA support, and the company reported revenue of 14.9 million euros for 2025 and targeted first BARDA commercial deliveries in 2026. In May 2025 it announced a new manufacturing module to scale up its ZENEO factory, and it published first half 2026 results in September 2026.
Midazolam addresses seizures from nerve agent poisoning, which is the link to chemical defence. Contract values and regulatory approval dates were not read.
Ownership
Publicly listed on Euronext Growth Paris (ALCJ)
Parent: none (publicly listed) (checked)
Sources (5)
- https://crossject.com/en/governance/
- https://crossject.com/wp-content/uploads/2026/03/CP-RESULTAT-2025-EN.pdf
- https://crossject.com/wp-content/uploads/2026/04/CORP-SITE-INTERNET-V27-03-2026.pdf
- https://live.euronext.com/en/products/equities/company-news/2025-05-27-crossject-implements-new-manufacturing-module-scale
- https://crossject.com/wp-content/uploads/2026/09/CROSSJECT-Reports-Its-First-Half-2026-results.pdf
Not verified or not found
- BARDA contract values: not read.
- Regulatory approval status and dates for ZEPIZURE: not read.
Questions
What does Crossject do?
Crossject is a French maker of needle-free auto-injectors. Under a BARDA Project BioShield partnership it is developing ZENEO midazolam autoinjectors for emergency use, such as nerve-agent seizures.
Where is Crossject based?
HQ (as found): Dijon. HQ country: FR.
Who owns Crossject?
Publicly listed on Euronext Growth Paris (ALCJ). Parent: none (publicly listed) (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction